24 February 2020 - Perrigo and its partner, Catalent Pharma Solutions, today announced that the U.S. FDA has approved Perrigo's abbreviated new drug application for generic albuterol sulphate inhalation aerosol, the first AB-rated generic version of ProAir HFA.
Perrigo is launching a limited quantity of generic albuterol sulphate inhalation aerosol and, in collaboration with its development and manufacturing partner Catalent, is ramping up production to meet future demand.